Vernalis announces Italian launch of frovatriptan
29 September 2004
Frovatriptan launched in Italy by the Menarini Group
Vernalis (LSE: VER) announces today that frovatriptan has been launched in Italy by its partner, the Menarini Group. Frovatriptan will be marketed in Italy under two trade marks; Rilamigâ and Auradolâ by the Menarini Group of companies. The Italian migraine market is estimated to be worth approximately €55 million Euro (IMS). Frovatriptan is approved for the acute treatment of migraine in 16 European countries and is also marketed by the Menarini Group in Germany, Ireland, the UK, Austria and the Netherlands, with launches in other countries to follow in 4Q04 and in 2005.
“The launch of frovatriptan in Italy, Menarini’s largest market, is a significant step towards our objective of making this product available to migraine patients throughout Europe” said Simon Sturge, Chief Executive Officer of Vernalis.
Menarini
Founded in 1886, Menarini is a dynamic European pharmaceutical
company expanding rapidly in international markets. Menarini is the
largest Italian pharmaceutical company and one of the fastest
growing pharmaceutical companies in the world. Menarini’s
products are marketed in over 100 countries and in 2003 the
worldwide group turnover was over €1,800 million Euro.
----ends----
Enquiries:
Vernalis plc
Simon Sturge, Chief Executive Officer
Tony Weir, Chief Financial Officer
+44 (0)118 977 3133
Brunswick Group (for analyst, financial media
enquiries)
Jon Coles; Wendel Carson
+44 (0)20 7404 5959
